Metabolic Signaling
GLP-1
GLP-1 receptor agonist
GLP-1 Receptor Agonist
Research context
This compound is a GLP-1 analogue modified with an aminoisobutyric acid substitution at position 8 and a C18 fatty diacid chain, both of which extend half-life in published pharmacokinetic characterisation. Research examines GLP-1 receptor binding affinity, cAMP accumulation in receptor-transfected cell lines, and albumin binding kinetics.
Common assays: GLP-1R binding affinity · cAMP accumulation · Albumin binding kinetics · DPP-4 resistance
Specification
| Designation | GLP-1 receptor agonist |
|---|---|
| Full name | GLP-1 Receptor Agonist |
| Sequence | Acylated GLP-1(7-37) analogue with Aib8 and Arg34 substitutions |
| CAS number | 910463-68-2 |
| Molecular formula | C187H291N45O59 |
| Molecular weight | 4113.58 g/mol |
| Formats | 10 mL Vial · 15 mL Nasal Spray · 15 mL Oral Spray |
| Solubility | Bacteriostatic water, sterile water |
| Storage | Lyophilised: 2–8 °C, protected from light. Reconstituted: 2–8 °C. |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Lau J, Bloch P, Schäffer L, et al.Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutideJournal of Medicinal Chemistry · 2015 Find on PubMed ↗
- Knudsen LB, Lau J.The discovery and development of liraglutide and semaglutideFrontiers in Endocrinology · 2019 Find on PubMed ↗
Common questions
What modifications distinguish this analogue from native GLP-1?
An aminoisobutyric acid substitution at position 8 confers resistance to DPP-4 cleavage, and a C18 fatty diacid side chain promotes albumin binding. Both were characterised in published pharmacokinetic work.
How is identity confirmed analytically?
By LC-MS against the theoretical mass of 4113.58 g/mol, with RP-HPLC for purity. For a peptide of this length, peptide content by nitrogen determination is reported separately from net weight.
Same pathway
Related compounds
GLP-2 Dual Agonist
Dual GIP/GLP-1 receptor agonist
A synthetic dual agonist at both GIP and GLP-1 receptors, studied in comparative incretin signalling.
GLP-3 Triple Agonist
Triple GLP-1/GIP/glucagon receptor agonist
A synthetic triple agonist at GLP-1, GIP and glucagon receptors, studied in multi-receptor incretin research.
GLP-3 Triple / GLP-1 Blend
Dual agonist blend
A prepared blend combining a triple receptor agonist and a GLP-1 receptor agonist in a single metered format.